Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study

[1]  Olaf Johan Hartmann-Johnsen,et al.  Time trends in axilla management among early breast cancer patients: Persisting major variation in clinical practice across European centers , 2016, Acta oncologica.

[2]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  C. Denkert,et al.  Reply to Ki67 in breast cancer: a useful prognostic marker! , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  John M S Bartlett,et al.  An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.

[5]  E. Ardanaz,et al.  Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. , 2013, Gynecologic oncology.

[6]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Federico,et al.  Relative and disease-free survival for breast cancer in relation to subtype: a population-based study , 2013, Journal of Cancer Research and Clinical Oncology.

[8]  M. Mathieu,et al.  Outcome in breast molecular subtypes according to nodal status and surgical procedures. , 2013, American journal of surgery.

[9]  E. van Limbergen,et al.  Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[11]  S. González,et al.  Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010. , 2012, Breast.

[12]  G Rauch,et al.  Outcome analysis of patients with primary breast cancer initially treated at a certified academic breast unit. , 2012, Breast.

[13]  H. Park,et al.  Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. , 2012, Breast.

[14]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[15]  Pierre-Marie Martin,et al.  Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review , 2011, Breast Cancer Research and Treatment.

[16]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Bani,et al.  Quality Assured Health Care in Certified Breast Centers and Improvement of the Prognosis of Breast Cancer Patients , 2011, Oncology Research and Treatment.

[18]  Graham A. Colditz,et al.  Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study , 2011, Breast Cancer Research and Treatment.

[19]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[20]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Wessels,et al.  Molecular subtyping of breast cancer: ready to use? , 2010, The Lancet. Oncology.

[22]  Jorge S Reis-Filho,et al.  The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade , 2010, The Journal of pathology.

[23]  M. Beckmann,et al.  Certification of breast centres in Germany: proof of concept for a prototypical example of quality assurance in multidisciplinary cancer care , 2009, BMC Cancer.

[24]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[25]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[27]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[28]  R. Walker,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2005 .

[29]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[31]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[33]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.

[34]  F. Ederer,et al.  The relative survival rate: a statistical methodology. , 1961, National Cancer Institute monograph.

[35]  Yu Shyr,et al.  Nationwide trends in mastectomy for early-stage breast cancer. , 2015, JAMA surgery.

[36]  A. Jemal,et al.  Breast cancer statistics, 2013 , 2014, CA: a cancer journal for clinicians.

[37]  R. Heidel,et al.  Prognostic Value of Breast Cancer Subtypes, Ki‐67 Proliferation Index, Age, and Pathologic Tumor Characteristics on Breast Cancer Survival in Caucasian Women , 2013, The breast journal.

[38]  C. Perou,et al.  The genomic landscape of breast cancer as a therapeutic roadmap. , 2013, Cancer discovery.

[39]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[40]  青儀 健二郎,et al.  What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及 , 2006 .

[41]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[42]  A. Jemal,et al.  Breast Cancer Statistics , 2013 .